Il Tempo: Iannelli (Favo): "Coinvolgere pazienti in trial atto di democrazia sanitaria"

Roma, 18 mar. (Adnkronos Salute) - "Il coinvolgimento dei pazienti nella ricerca clinica - una ricerca 'con' i pazienti e non solo 'sui' pazienti - deve essere considerato un vero e proprio atto di democrazia sanitaria. Non si tratta soltanto di un obbligo giuridico (la normativa riconosce il ruolo delle associazioni che rappresentano i bisogni dei pazienti a tutti i livelli), ma prima ancora etico: integrare il punto di vista dei pazienti fin dalle fasi iniziali, a partire dalla coprogettazione degli studi, significa rendere la ricerca più giusta, equa ed efficace, capace di rispondere concretamente ai bisogni reali". Lo sottolinea Elisabetta Iannelli, segretario generale della Favo (Federazione italiana delle associazioni di volontariato in oncologia), intervenendo a Roma alla presentazione del Working Paper 'Protagonista della ricerca. Il paziente al centro dei trial in oncologia ed emato-oncologia', realizzato da Teha (The European House - Ambrosetti) con il contributo non condizionante di Amgen.
Il coinvolgimento dei pazienti, attraverso le associazioni e le reti che li rappresentano, "consente infatti di individuare in modo più completo i bisogni di salute e di cura, includendo anche aspetti fondamentali come la qualità della vita, che ancora oggi non sempre rientrano tra gli endpoint degli studi clinici", evidenzia Iannelli. Questo "approccio - rimarca - favorisce un progressivo avvicinamento tra ricerca e pazienti e può contribuire anche a migliorare la partecipazione agli studi, oggi ancora limitata perché c'è un problema di reclutamento". In questo contesto "un ruolo cruciale è svolto proprio dalle associazioni dei pazienti, che attraverso l'informazione e la sensibilizzazione possono aiutare a diffondere una maggiore consapevolezza sulle opportunità offerte dalla ricerca clinica e facilitare il coinvolgimento dei potenziali partecipanti".

Iannelli (Favo): "To involve patients in trial processes is an act of democratic healthcare."

Rome, March 18 (Adnkronos Salute) - "The involvement of patients in clinical research – a research ‘with’ patients and not just ‘on’ patients – must be considered a true act of healthcare democracy. This is not only a legal obligation (the regulation recognizes the role of associations that represent the needs of patients at all levels), but even before that, ethical: integrating the patient’s perspective from the initial phases, starting with the co-design of studies, means making research fairer, more equitable, and more effective, capable of concretely responding to real needs.” This is emphasized by Elisabetta Iannelli, general secretary of Favo (Federazione italiana delle associazioni di volontariato in oncologia), speaking in Rome at the presentation of the Working Paper ‘Protagonista della ricerca. Il paziente al centro dei trial in oncologia ed emato-oncologia’, produced by Teha (The European House - Ambrosetti) with the non-conditioning contribution of Amgen.

The involvement of patients, through the associations and networks that represent them, “allows for a more complete identification of health and care needs, including fundamental aspects such as quality of life, which still do not always fall within the endpoints of clinical trials,” Iannelli highlights. This “approach – she reiterates – favors a gradual rapprochement between research and patients and can also contribute to improving participation in studies, which is still limited because there is a recruitment problem.” In this context “a crucial role is played by patient associations, which through information and awareness campaigns can help to spread greater awareness of the opportunities offered by clinical research and facilitate the involvement of potential participants.”

#Iannelli( #AdnkronosSalute #ElisabettaIannelli #Amgen

https://www.iltempo.it/adnkronos/2026/03/18/news/iannelli-favo-coinvolgere-pazienti-in-trial-atto-di-democrazia-sanitaria--46867950/

Iannelli (Favo): "Coinvolgere pazienti in trial atto di democrazia sanitaria"

Roma, 18 mar. (Adnkronos Salute) -

#Amgen’s Dark Blue deal (up to $840m) is less about one preclinical asset and more about a trend: pharma is paying to remove proteins, not just block them. Feature: https://biotech.industryexaminer.com/amgen-dark-blue-protein-degrader-aml/ #Hematology #AML #Oncology #Biotech #Pharma #DrugDevelopment #ProteinDegradation #TechNews
Amgen’s $840m wager on Dark Blue shows why pharma keeps paying to make proteins disappear - Biotech Industry Examiner

On a cold Tuesday in early January, Amgen quietly made one of the more revealing oncology bets of the new year: it agreed to acquire Oxford-based Dark Blue

Biotech Industry Examiner
La saga de l'EPO

La saga de l'EPO...

広州モーターショー2025が“縮小ムード”、それでも躍進続く中国新興EV勢(上編)

https://fed.brid.gy/r/https://36kr.jp/447543/

Amgen CEO Bob Bradway announced that new clinical trial data show Repatha significantly reduces heart attack risk by 36% when combined with standard therapies, underscoring the importance of lowering LDL cholesterol for high-risk patients.
#YonhapInfomax #Amgen #Repatha #HeartAttackRisk #LDLCholesterol #ClinicalTrialResults #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=90246
Amgen CEO Says Cholesterol Drug Proven to Cut Heart Attack Risk by 36%

Amgen CEO Bob Bradway announced that new clinical trial data show Repatha significantly reduces heart attack risk by 36% when combined with standard therapies, underscoring the importance of lowering LDL cholesterol for high-risk patients.

Yonhap Infomax
Il y a 20 ans : Le fabricant d'EPO se pose en fier partenaire du Tour de Californie https://www.cyclisme-dopage.com/breves/breves-2005-11-06-tsr-ch.htm #cyclisme #dopage #EPO #AMGEN
Le fabricant d'EPO se pose en fier partenaire du Tour de Californie

La firme pharmaceutique américaine AMGEN, premier producteur mondial d'EPO (...), a défendu (...) son intention de parrainer le Tour cycliste de Californie, qui doit avoir lieu en février

Today was a historic day for Thousand Oaks as Amgen broke ground on a $600 million R&D center here. This investment, one of the largest in Ventura County history, will speed development of new medicines by putting research and process development under one roof.

As a global biotech leader Amgen can locate anywhere – but it chose Thousand Oaks because of our world-class workforce, excellent schools, abundant open space, and safe streets.

I’m looking forward to the scientific breakthroughs this new center will bring, right here in Thousand Oaks!

📷 1: Alex South; 📷 3: Josh Gray

#amgen #biotech #research #pharma #thousandoaks #venturacounty

O Que é uma Blue Chip? Tudo Que Você Precisa Saber#GuiadeNegociação #Amgen #BerkshireHathaway #Bluechips #CocaCola #DiversificaçãodePortfólio #estabilidadefinanceira #históricodedividendos #investimentos #pagamentosdedividendos #preservaçãodecapital Uma blue chip é uma empresa amplamente reconhecida, bem estabelecida e financeiramente sólida que é negociada publicamente. As blue chips geralmente vendem prod...
https://djltrading.com/o-que-e-uma-blue-chip-tudo-que-voce-precisa-saber?fsp_sid=17505
O Que é uma Blue Chip? Tudo Que Você Precisa Saber

Uma blue chip é uma empresa amplamente reconhecida, bem estabelecida [...]

Investimentos e Trading

🚀 Big news in biotech!
Amgen is investing $600M to build a cutting-edge center for science and innovation at its global HQ in Thousand Oaks, CA—driving advancements in biotechnology and healthcare solutions. 🌱

Meanwhile, Enveric Biosciences is relocating its HQ to Cambridge, MA, strengthening one of the world’s most dynamic biotech hubs.

👉 Full story: http://dlvr.it/TMw70V

#Biotech #Innovation #Healthcare #Amgen #EnvericBiosciences #LifeSciences #EconDev

Amgen Plans $600M Center To Advance Biotech Innovation

Amgen to create center for science and innovation at California headquarters. Enveric Biosciences relocates its headquarters to Cambridge, MA.

Business Facilities
Global markets saw key data and corporate moves: China's services PMI beat forecasts, US futures rose in Asia, and analysts predicted further S&P 500 gains on AI optimism, while major companies like Amgen and Klarna announced significant investments and IPO plans.
#YonhapInfomax #ChinaServicesPMI #SP500 #AIRevolution #Amgen #KlarnaIPO #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=80005
[Morning Major International Financial News]China August S&P Global Services PMI at 53.0, Slightly Above Expectations (Summary)

Global markets saw key data and corporate moves: China's services PMI beat forecasts, US futures rose in Asia, and analysts predicted further S&P 500 gains on AI optimism, while major companies like Amgen and Klarna announced significant investments and IPO plans.

Yonhap Infomax